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PrognosisThere is a need for a blood biomarker of disease activity in ALS. This marker needs to measure the loss of motor
neurones. Phosphorylated neuroﬁlament heavy chain (pNfH) in the serum is a biomarker of axonal injury.
Previous studies have found that levels of pNfH are elevated in ALS. We have performed a serial study of pNfH
levels in 98 subjects from our ALS clinic. There was signiﬁcant elevation of levels of pNfH in subjects with ALS
compared to controls, although there was considerable variability. In studies of individuals who had two or
more serial samples, we found that the levels of pNfH increased over time in the early stage of disease. Levels
were low in subjects with long survival. The rate of rise of pNfH was inversely correlated with survival. We
suggest that the initial level of pNfH is a marker of disease severity and that changes in pNfH levels are markers
of disease progression.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is a need for a biomarker of disease progression in amyotro-
phic lateral sclerosis (ALS), to assistwith prognosis and for use in clinical
trials [1,2] with a blood biomarker being most convenient [3].
Neuroﬁlament (Nf) heavy protein (NfH) is one of the three neuronal
cytoskeleton intermediate ﬁlament subunit proteins; the others being
neuroﬁlament medium protein and light protein [4]. Phosphorylated
NfH (pNfH) is a major constituent of axons and release of pNfH protein
is considered to be a biomarker of axonal injury [5]. In cerebrospinal
ﬂuid (CSF), accumulation of pNfH has been demonstrated in animal
models of spinal cord injury and brain injury [5,6]. In the blood, elevated
levels of pNfH have been demonstrated in animals with focal brain inju-
ry [7] and focal brain ischaemia [8]. In human subjects, elevated levels of
pNfH have been found in the serum of subjects with acute ischaemic
stroke [9,10] and subjects with acute brain injury after cardiac arrest
[11]. Since the pathology of ALS is death of motor neurones and loss of
their axons, pNfH is a possible biomarker of disease progression in ALS.
Studies to date have found elevation of pNfH in CSF in animalmodels
[5,6] and in humans with ALS [12,13]. Elevated levels of pNfH have also
been demonstrated in the blood of subjects with ALS [14,15]. There is
one study showing that CSF and plasma levels of pNfH are correlated
[16]. Histological studies have demonstrated the loss of NfH and pNfH
from brain and spinal cord tissues in ALS subjects [17], and that there
is aggregation of Nf within cells as disease progresses [18]. Levels of1 738327447.
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. This is an open access article underpNfH have been linked to disease severity, with the rate of change of
ALS functional rating scale (ALSFRS) being greater in subjects with
higher levels of pNfH in the blood [18] and high levels early in disease
being linked with more rapid progression [15]. We have performed a
study of subjects from our ALS clinic, to measure pNfH levels over
time and to correlate these with survival. Even in subjects who fulﬁl
the diagnostic criteria for clinically deﬁnite disease [19], ALS is heteroge-
neous [20]. The variable features of ALS include length of survival, with a
subgroup of patients with ALS showing survival greater than 5 years
[21], site of onset and relative severity of upper and lower motor
neurone signs [20,22–24]. These features could be associated with
different rates of progression of disease, so we have also studied levels
of pNfH in subjects with different clinical features.
2. Materials and methods
2.1. Subjects and blood collection
For this study we used samples from 98 consecutive subjects from
our ALS clinic who consented to the study. Subjects with typical ALS
fulﬁlled the criteria for diagnosis of ALS at the time of blood collection,
and had mixed upper and lower motor neurone signs [19]. We also in-
cluded patients from the clinic who had both upper and lower motor
neurone signs, and fulﬁlled the diagnostic criteria, but had predominant
uppermotor neurone (UMN)weakness, as previously described [22,25]
or predominant lower motor neurone (LMN) weakness, as described
[25,26]. At the end of the study, 65 patients were deceased. Survival
was calculated from the onset of disease until death or the end of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Subgroups of ALS subjects.
Patients were divided according to whether they had typical ALS with mixed upper and
lower motor neurone signs, or had ALS with predominant upper or lower motor neurone
weakness, and according to the site of onset. The number of subjects in each group is
shown. The median (interquartile range) of the age and the survival of the subjects in
these groups are also shown.
Number of
subjects
Median (IQR) age at
onset (years)
Median (IQR) survival from
onset until death or
censoring (years)
Phenotypes
Typical ALS 63 60.86 (15.85) 3.16 (2.18)
UMN
predominant
10 56.29 (24.48) 6.32 (1.99)
LMN
predominant
25 57.57 (14.17) 4.77 (3.14)
Site of onset
Bulbar 32 62.79 (9.54) 2.81 (1.76)
Upper limb 32 58.00 (17.05) 4.05 (2.65)
Lower limb 34 57.11 (12.59) 4.64 (3.51)
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was collected on up to 9 occasions with a total of 223 ALS samples.
We also collected blood from 61 healthy controls. The details of the
subjects are shown in Table 1. The subjects with typical ALS, and UMN
and LMN predominant diseases are shown in Table 2. The site of onset
(bulbar, upper limb or lower limb) was noted and the numbers in
these groups are also shown in Table 2. Subjects were evaluated with
the ALS functional rating scale—revised (ALSFRS-R) [27]. This was not
done systematically, but the ALSFRS-R score was recorded at the time
of blood collection on at least one occasion on 50 subjects and on mul-
tiple occasions on 24 of those subjects. For the subjects with multiple
recorded values, we calculated the rate of change of ALSFRS-R. Our
study included subjects with typical ALS with short survival and also
included subjectswith clinically deﬁnite ALSwhohad prolonged surviv-
al. To study these two groups separately, we used an arbitrary cutoff,
and classed subjects into those with survival of b1500 days and those
with N1500 days.
2.2. Blood collection
Venous blood (6 ml) was taken into a serum tube (BD Vacutainer
Plus Red Serum Tube, Cat# 367837) and the tube was left in a standing
position at room temperature for 30 min to allow blood clotting. The
sample was then centrifuged at 1500 rpm for 10 min at room tempera-
ture. The serum was separated and aliquots were stored at−80 °C.
2.3. pNfH ELISA
The serum concentrations of pNfH were detected with a pre-coated
pNfH enzyme linked immune-sorbent assay (ELISA) kit, using polyclon-
al antibody to NfH (EnCor Biotechnology Inc., Gainesville, FL, USA) [5].
We used undiluted serum. The assay was performed according to the
manufacturer's instructions. In brief, 50 μL of undiluted serum from
patients and controls was added in triplicate. A standard curve was pre-
pared for each plate using 12 serial doubling dilutions of puriﬁed bovine
pNfH protein (provided by the kit), ranging from 0–12.5 ng/ml. The
reactionwas developed using 100 μL of Trimethylbenzidine (TMB)-per-
oxidase, and subsequently stopped using 50 μL of 2 N sulphuric acid.
Between the loading of the serum and the addition of the detection
antibody and also between the addition of the detection antibody and
the addition of TMB-peroxidase, the ELISA plate was incubated for 1 h
at room temperature. Plates were washed 10× between incubation
steps using the recommended wash buffer. Absorbance values were
determined by reading the plates at 450 nm using a Paradigm Plate
Reader (Beckman Coulter, Gladesville, Sydney, Australia). Serum pNfH
levels for all groups were calculated from the standard curve.
We selected samples from one subject with a high value and one
with a low value of pNfH and studied these samples in multiple ELISA
plates. The coefﬁcients of variation were 0.33 and 0.38, respectively.
We did not make a systematic study of the possibility of a “hook effect”,
whereby the concentration of protein measured by the assay is greater
when samples are diluted [28,29]. However, we studied two samples
undiluted, and in 1:2 and 1:4 dilutions. For these samples, there was
an increase in the concentration of pNfH after dilution, suggestive of a
“hook effect”.Table 1
Clinical features of subjects.
This table shows the clinical details of the healthy controls and the ALS subjects. The healthy co
collected.
Total
number
Mean age
(range)
Percent
female
Number with single
sample
Healthy subjects 59 48 (21–95) 61 –
ALS subjects 98 61 (32–81) 44 432.4. Calculation of rate of rise of pNfH and rate of change of ALSFRS-R
Wecalculated the rate of rise of pNfH, by using the slope of the linear
regression curve for all available values. We calculated the rate of
change of ALSFRS-R by using the slope of the linear regression curve
for all available values.2.5. Statistical methods and graphs
Statistical analysis, curve ﬁtting and graphswere donewith GraphPad
Prism version 5.00 for Windows (GraphPad Software, San Diego,
California, USA). Groups were compared using Kruskal–Wallis one-way
ANOVA corrected for multiple comparisons, and Mann–Whitney test for
comparing two groups. The rate of change of pNfH and of the ALSFRS-R
was the slope of the linear regression curve. Linear regression analysis
was used to correlate pNfH levels and rate of rise of pNfH with survival
and ALSFRS-R and rate of change of ALSFRS-R.3. Results
3.1. Serum levels of pNfH are elevated in subjects with ALS
Fig. 1 shows the levels of pNfH in all samples combined, for the ﬁrst
sample and for the peak samples,whichwere the highest recorded level
for subjects with multiple samples, and the ﬁrst value for subjects with
only one sample. The levels were signiﬁcantly greater in subjects with
ALS than in healthy controls. A value greater than 1.5 ng/ml was only
seen in ALS subjects. As with clinical trials of ALS, our study included
subjects with long survival. When the subjects are subdivided into
those who survived until death or censoring for less than 1500 days,
and those with survival greater than 1500 days, it can be seen that
those with a shorter survival time have higher pNfH levels and peak
pNfH levels. This suggests that higher levels are found in more severe
and rapidly progressing disease with shorter survival.ntrols (HC) had only one sample of blood collected. The ALS subjects had up to 9 samples
Number with two
samples
Number with three
samples
Number with four or more
samples
– – –
55 34 14
Fig. 1. pNfH levels. This shows the levels of pNfH in healthy controls (HC), the total ALS
group, the ALS subjects with survival less than 1500 days and the ALS subjects with survival
more than 1500 days. We show the results for all the samples that were collected (ALL) and
theﬁrst samples (1st) and the peak levels (PEAK),which are the peak levels ifmore than one
sample was collected, and the ﬁrst level if only one sample was collected. Individual results
are shown as open circles and the median value for each group is shown as a horizontal
line. There is signiﬁcant elevation of pNfH levels in subjects with ALS, compared to controls
(Kruskal–Wallis one-way ANOVA corrected for multiple comparisons, asterisk indicates
p b 0.0001). The greatest levels are seen in the subjects with survival b 1500 days.
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For those subjects with serial samples, the results are shown in
Fig. 2A. In 33 of 55 subjects (60%) there was a rise of pNfH levels from
the ﬁrst to the second sample, and in 21 of 34 subjects (62%) there
was a rise from the ﬁrst to the third sample. For all samples that were
collected, Fig. 2B and C show the average trajectories of pNfH levels
for subjects with survival less than 1500 days, and those with survival
greater than 1500 days, respectively, ﬁtting a second order polynomial
curve. These show that, on average, there was a rise and then a fall in
pNfH levels, but there is considerable variability among subjects.Fig. 2. pNfH serial studies. Panel A shows the pNfH levels for the subjects who had serial samp
shown as black circles and the serial samples for each individual are linked by a line. Many sub
In Panels B and C we show all of the samples, including those where only one sample was colle
less than 1500 days, with a second order polynomial curve ﬁtted. Panel C shows the values for a
These curves show that on average there is a rise and fall of pNfH levels over time, but it mustFig. 3A shows the values for the ﬁrst, second, third and fourth and
later samples. The levels at each collection were greater than for con-
trols. The levels of pNfH were greater in the later samples. For all sam-
ples that were collected, as shown in Fig. 3B and C, when subjects
were subdivided into those with survival less than or greater than
1500 days, and the samples stratiﬁed according to the time after onset
of disease in 6 monthly epochs, there was a rise in levels as disease
progressed, and a fall later in disease.
3.3. Relationship to survival of pNfH levels and of the rate of change of pNfH
levels
To determinewhether the levels of pNfH are related to survival from
symptom onset, in the upper panel of Fig. 4A we plot all of the pNfH
levels against survival time. This shows an inverse relationship between
pNfH levels and survival, with linear regression analysis, although some
subjects with short survival had low pNfH levels. There was also an
inverse relationship between survival and the ﬁrst pNfH level (Fig. 4B)
and the peak pNfH level (Fig. 4C). To determine if the rate of rise in
pNfH is related to survival, for those subjects with serial samples, we
also calculated the rate of rise of pNfH, using all available values, and
plotted this against survival. In subjects where there was a decline in
pNfH, the rate of rise was taken to be zero. This is shown in the lower
panel of Fig. 4D. There is a signiﬁcant relationship between the rate of
rise of pNfH and survival.
Having shown that the values of pNfH rise with time, and that there
is a relationship between survival and the peak pNfH level, but not the
ﬁrst pNfH level, we have also plotted the relationship of survival and
pNfH for samples collected at different times after onset of disease.
This is shown in Fig. 5. For the samples collected 0–12 months after
onset, the survival was generally less than 1000 days, and there was
no correlationwith survival. For the samples collected at 12–24months
after onset, and those collected at 24–36 months after onset, higher
values of pNfH were associated with reduced survival. The samples
collected after 36months from onset were from subjects with long sur-
vival, and for these samples, there was no correlation with survival.
These data are in accord with our serial studies that show that levelsles, according to the time after onset that the sample was collected. Individual results are
jects showed an increase in levels with time, but later in the disease the levels were low.
cted and those with serial samples. Panel B shows the values for all subjects with survival
ll subjects with survivalmore than 1500 dayswith a second order polynomial curve ﬁtted.
be noted that there is considerable variability among subjects.
Fig. 3.pNfH levels over time. Panel A shows the levels of pNfH in theﬁrst, second, third and
fourth or later samples. The horizontal bars represent the median values. The subjects
were divided into those with survival less than 1500 days and those with longer survival.
The later samples showed higher values than the ﬁrst sample (Kruskal–Wallis one-way
ANOVA corrected for multiple comparisons, asterisk indicates p b 0.05). In Panels B and
C we show all of the samples, including those where only one sample was collected and
those with serial samples. Panels B and C, which show the results from subjects with
survival less than 1500 days and more than 1500 days, respectively, show the samples
grouped according to the time after onset of disease that the sample was collected, in 6
monthly epochs. There was a rise in levels as disease progressed, and a later decline.
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of rise of pNfH may be a better predictor of survival.
3.4. Relationship to clinical features of ALS subjects
We examined the relationship of pNfH levels and the rate of rise of
pNfH to clinical features of the ALS subjects. There was no signiﬁcant
difference between males and females in pNfH levels or the rate of
rise of pNfH (Supplementary Fig. 1). Table 2 gives the numbers ofsubjects with typical ALS, UMN predominant and LMN predominant
phenotypes. There was no signiﬁcant difference among the groups in
the levels of pNfH or the rate of rise of pNfH (Supplementary Fig. 2).
The numbers of subjects with onset in bulbar, upper limbs and lower
limbs are shown in Table 2. There was no difference in the pNfH levels
or the rate of rise of pNfH among these groups (Supplementary Fig. 3).
Therewas no signiﬁcant difference between the Rilutek treated subjects
and untreated subjects in the levels of pNfH. There was a reduction in
the rate of rise of pNfH in subjects on Rilutek, this was not statistically
signiﬁcant (Supplementary Fig. 4). In Fig. 6A we show that there was
no association between age and pNfH levels in healthy controls, but
there was a signiﬁcant association between the age and the peak levels
of pNfH protein (Fig. 6B). There was no signiﬁcant association between
age and the rate of rise of pNfH protein (Fig. 6C). In our subjects there
was a signiﬁcant inverse association between age at onset and survival
from onset (Supplementary Fig. 5).
We examined the relationship of pNfH and rate of change of pNfH to
the ALSFRS-R score at the time of blood collection and to the rate of
change of ALSFRS-R. There was no relationship of the pNfH level to
the ALSFRS-R at the time of blood collection (data not shown). As
shown in Fig. 7A, there was an apparent inverse relationship between
peak pNfH levels and rate of change of ALSFRS-R. For the small number
of subjects for whom this data was available, there was a greater rate of
rise of pNfH in those with a greater rate of decline of ALSFRS-R, but this
was not statistically signiﬁcant (Fig. 7B).
4. Discussion
We report the results of a serial study of levels of pNfH in subjects
with ALS, using a commercially available ELISA kit, with a polyclonal
antibody to pNfH. Overall, serum pNfH levels were signiﬁcantly higher
in ALS subjects than in control subjects, as has been shown previously
[14,18]. After CNS injury, pNfH is released into the extracellular ﬂuid
from where it diffuses into the CSF and ﬁnally enters the blood stream
via the arachnoid villi. We have previously shown that pNfH levels are
elevated after stroke [9] and others have found that pNfH levels are
elevated in multiple sclerosis [30] which indicates that pNfH can enter
the blood after CNS damage in humans. After degeneration of peripheral
axons, we expect that pNfH could readily enter the blood stream. There-
fore we expect that the pNfH levels in ALS will reﬂect damage of both
upper and lower motor neurones.
In our serial study, we found that, in many subjects, the levels of
pNfH increased over time in the early stage of disease. It also shows a
possible decline in levels in the later part of disease. There have been
two previous serial studies of pNfH levels in humans. One study follow-
ed patientsmonthly for 4months and foundno change in levels of pNfH
[18]. This is a short time frame compared to our study, and does not
show what happens with prolonged observation. The only other serial
study, which followed patients for three years, also showed that levels
changed with time, and that for some subjects the levels increased
and for others the levels decreased [15]. Our study gives similar results.
The novel aspect of our study is that we followed patients for prolonged
periods, and in 68 of the 98 subjects, the follow-up was until death. In a
study in SOD1mutantmice, it has been shown that pNfH levels increase
as disease progresses up to day 120 [31]. This study did not extend to
the end stage of disease (150–180 days) when, as we have shown,
few axons remain [32], and we suggest that it is possible that the levels
would decline if mice were samples at this later stage.
Our study included some subjects with ALSwith prolonged survival,
as has been reported in 14% of ALS subjects [21]. We found that pNfH
levels were greater in subjects with shorter survival, and that there
was an inverse correlation between pNfH levels and survival. It has
previously reported that high levels early in disease are linked with
more rapid progression [15]. We calculated the rate of rise of pNfH
levels and found that this was inversely correlated with survival.
These data suggest that high levels and a rapid increase in pNfH levels
Fig. 4. Survival and pNfH levels. Panel A shows the relationship between pNfH levels and survival time, for all samples, using linear regression analysis. There was a signiﬁcant inverse
correlation. Note that a logarithmic scale is used for the survival time. Panel B shows the relationship between the value of pNfH in the ﬁrst sample collected from each subject and the
survival. There was a trend to higher values of pNfH being associated with reduced survival, but this was not clinically signiﬁcant. Panel C shows the inverse relationship between the
peak value of pNfH and survival. This was signiﬁcant. Panel D shows the relationship of the rate of rise of pNfH and survival. There was a signiﬁcant inverse relationship between the
rate of rise of pNfH and survival, using linear regression analysis. Note that a logarithmic scale is used for the rate of rise of pNfH.
Fig. 5. Effect of timing of sample on relationship between pNfH levels and survival. In this ﬁgure we have grouped all the samples according to the time after onset of symptoms that the
samples were collected. We then plotted the relationship between the pNfH level and survival for each of these groups of samples. For the samples collected 0–12 months after onset
(Panel A), the survival was generally less than 1000 days, and there was no correlation with survival. For the samples collected at 12–24months after onset (Panel B), and those collected
at 24–36 months after onset (Panel C), higher values of pNfH were associated with reduced survival. The samples collected after 36 months from onset were from subjects with long
survival (Panel D) and for these samples, therewas no correlationwith survival. Thesedata are in accordwith our serial studies that show that levels of pNfH increase as disease progresses,
and that the rate of rise of pNfH may be a better predictor of survival.
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Fig. 6. pNfH levels and age. Panel A shows that there was no relationship between pNfH
levels and age in the control subjects. Panel B shows the relationship between age of the
subject at the time of sample collection and the levels of pNfH. This was signiﬁcant,
using linear regression analysis. Panel C shows that there was no signiﬁcant relationship
between age and rate of rise of pNfH.
Fig. 7.pNfH levels andALSFRS-R. Panel A shows the relation between thepeakpNfH level and th
was a signiﬁcant inverse correlation. Panel B shows the relationship between the rate of change
was not statistically signiﬁcant. Note that a logarithmic scale is used for the rate of rise of pNfH
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We note that some patients with low pNfH levels had short survival.
This could occur if the levels were underestimated because of the devel-
opment of antibodies to pNfH, as has been described [15,33]. However,
another issue is that survival is not always related to disease severity,
and can be shorter in subjects with early respiratory involvement and
longer in subjects treated with non-invasive or invasive ventilation.
To account for the increase in levels of pNfH as disease progresses, and
the possible decline in levels at the end of the disease course, we suggest
that the level of pNfH in the blood would be related to the number of
axons being degraded in per unit of time, which would add pNfH to the
blood. Neuroﬁlaments are susceptible to proteolysis within cells [34,35]
and are likely to be removed from the circulation by proteolysis, which
would clear pNfH from the blood. In human ALS, little is known about
the kinetics of the loss of motor neurones, but this would be dependent
on the number of axons remaining and the rate of axonal degeneration.
Possiblemathematicalmodels of the loss ofmotor neurones include a lin-
ear decay, an exponential decay or an accelerating process. There has
been a theoretical study of this topic [36] but there is little data to indicate
which of these models applies to human ALS, although in inherited neu-
rodegenerative conditions there is support for the one-hit model [37],
which implies exponential decline. For the lower motor neurone, we
have data suggesting that the loss of axons from a single muscle follows
an exponential decay [38]. However, the disease spreads from the region
of onset to other regions and asmore regions become involved in the ini-
tial stage of disease, the number of degenerating motor neurones would
be expected to increase. Later in the disease, when few motor neurones
remain, we would argue that fewer cells would die per day, and this
would be consistent with our data and the data of Lu et al. showing that
levels decline later in the course of disease [15].
Another issue is whether the decline in levels in the later stage of
disease could be due to increased aggregation of Nf in the later stage
of disease, which could reduce the number of binding sites available
for antibody binding. There is evidence of aggregation of neuroﬁlament
in neurodegenerative disease [17]. However, we think this is less likely
as an explanation for a decline in levels as disease progresses. We
suggest that Nf may progressively aggregate within a neurone, until
that neurone dies, releasing aggregated protein. If all cells die in a simi-
lar fashion, then all the Nf released from dead neurones would be
expected to show similar levels of aggregation. Therefore, higher levels
should still represent greater numbers of neurones dying in a given
time, and lower levels would indicate fewer cells dying.
To categorize our subjects into those with shorter disease duration
and those with longer disease duration, we used an arbitrary cutoff
of 1500 days (4.1 years) because patients with typical ALS are usually
thought to have a life expectancy of 3–5 years, and those with longer dis-
ease duration can be considered to have longer than expected survival. In
more rapidly progressing disease, wewould expect higher levels of pNfH,
particularly in the early stages of disease, as we have shown, with highere rate of rise of ALSFRS-R, for the subjectswhohad serialmeasurements of ALSFRS-R. There
of ALSFRS-R and the rate of rise of pNfH. Therewas an apparent inverse correlation, but this
.
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subjects with survival more than 1500 days.
We found no correlation between the levels of pNfH and ALSFRS-R,
which is similar to the results of others [14].We found some association
between the initial pNfH levels with the rate of change of ALSFRS-R, as
has previously been shown [18]. There was also a relationship between
the rate of rise of pNfH and the rate of change of ALSFRS-R, again sug-
gesting that the rate of change of pNfH holds promise as amarker of dis-
ease progression.
We found an association of pNfH levels with age, as has been found
previously [18]. This does not appear to be due to greater background
levels in older subjects, since we found no signiﬁcant association be-
tween pNfH levels and age in the control subjects. There was no signif-
icant association of age with the rate of rise of pNfH, which could be
related to the lower number of subjects in this group. Older age
is known to be associated with worse prognosis of ALS [39], and in our
cohort this was the case. This is consistent with our ﬁnding of increased
pNfH levels in older subjects and that pNfH levels are associated with
survival. We found no association between pNfH levels, or the rate of
rise of pNfH levels, and the site of onset, the phenotype of subjects or
the use of Rilutek. We have previously found that subjects with upper
or lower motor neurone predominant disease have a longer half life of
motor units [25], but this was not reﬂected in the levels of pNfH, sug-
gesting that pNfH levels are not as sensitive as measurements of neuro-
nal half life. We did not ﬁnd an effect of Rilutek on pNfH levels in ALS
patients, which was in contrast to the previous ﬁndings [14]. There
was a slight decrease in the rate of rise of pNfH in subjects on Rilutek,
but this was not statistically signiﬁcant.
There are some limitations of our study. One limitation is thatwe did
not use any methods to disrupt Nf aggregates that may occur in ALS as
part of the pathological process [28]. This could lead to an underestima-
tion of the levels of pNfH, if binding sites are blocked in aggregated
protein. Indeed, we found that the levels measured in diluted serum
were higher than in undiluted serum, suggesting that the “hook effect”
was present. This needs to be addressed in further studies, and there
needs to be standardization of assay for multi-centre studies [29,40].
Another limitation of our study is that we collected blood from the
ﬁrst visit to our ALS clinic and this meant that, for some subjects, the
ﬁrst sample was collected late in the course of disease, and it would
be preferable if all the ﬁrst samples were collected as soon as possible
after diagnosis. Other limitations of our study are that we did not collect
serial samples for all patients. For consistency, we plotted a straight line
to obtain the rate of rise of pNfH, and it is possible that the relationship
between pNfH levels and time is more complex, and this should be fur-
ther explored.
In summary, we have conﬁrmed that levels of pNfH are elevated in
ALS, and that high levels are associated with worse survival, and war-
rants further exploration as a prognostic marker in ALS. We have
shown that the rate of rise of pNfH levels is inversely related to survival,
and we suggest that this is a measurement that could be used in clinical
trials of therapies to reduce disease progression. In the futuremore pro-
spective studies are required and it would be helpful to the ﬁeld if
methods could be standardized, including the use of measures to over-
come protein aggregation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jns.2015.04.032.
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